Startup Orbital Therapeutics brings Bristol Myers Squibb an in vivo cell therapy in development for treating autoimmune disease. With the deal, BMS joins AstraZeneca, AbbVie, and Gilead Sciences in turning to M&A as a way to get in vivo cell therapy assets and technologies.
The post BMS Joins the In Vivo Cell Therapy Chase With $1.5B Orbital Therapeutics Acquisition appeared first on MedCity News.
